A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome
- 31 August 1992
- journal article
- Published by Elsevier in Medical Hypotheses
- Vol. 38 (4) , 329-333
- https://doi.org/10.1016/0306-9877(92)90027-a
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Dopamine D2 Receptor Imaging with SPECT: Studies in Different Neuropsychiatric DisordersJournal of Cerebral Blood Flow & Metabolism, 1991
- Dopamine Receptor Occupancy and Plasma Haloperidol LevelsArchives of General Psychiatry, 1989
- Recurrent neuroleptic malignant syndrome due to haloperidol and amantadineBiological Psychiatry, 1989
- Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic DrugsArchives of General Psychiatry, 1988
- Neuroleptic malignant syndrome: review and analysis of 115 casesBiological Psychiatry, 1987
- Neuroleptic-Induced Extrapyramidal Symptoms With FeverArchives of General Psychiatry, 1986
- Neuroleptic malignant syndromeAmerican Journal of Psychiatry, 1985
- Case report of neuroleptic malignant syndrome associated with withdrawal from amantadineAmerican Journal of Psychiatry, 1984
- Neuroleptic Malignant Syndrome-like State Following a Withdrawal of Antiparkinsonian DrugsJournal of Nervous & Mental Disease, 1981
- Neuroleptic malignant syndromeNeurology, 1981